- About us
- Hospitals and centres
- Patients and visitors
- Join our team
- Get involved
- Clinician resources
- Refer your patient
The available CCB sample holdings are all from consented donors with have been diagnosed with a haematological malignancy.
Bone marrow and peripheral blood biospecimens are only obtained when a patient/donor undergoes diagnostic and/or follow-up procedures as part of their specific treatment plan.
Wherever possible, a selection of sample types are then made from the donated bone marrow and peripheral (see table below).
Time points where bone marrow and/or peripheral blood are routinely collected on donors include:
A donor may have one, some or all time points stored, and may be undergoing either standard treatment for their disease or be enrolled on a specific clinical trial.
All donor baseline samples registered in the CCB database have a confirmed haematological malignancy and have been classified within the database according to the World Health Organization (WHO) Tumours of Haematopoietic and Lymphoid Tissue.
CCB samples are standardly processed as per the tables below as follows:
|Bone marrow, peripheral blood, processed into vials of:||By product:||For lab studies, e.g.:|
|Cell pellet||DNA||Genomic studies|
|Plasma aliquot and/or serum||Plasma or serum||Cytokines, proteomics|
|Cyropreserved cells||Viable cells||Cell culture, in vitro drug effects|
|Other sample types held:||By product:||For lab studies, e.g.:|
|Lymph nodes||DNA||Genomic studies|
|Other tissue (site) biopsies||DNA||Genomic studies|
The above list is not exhaustive; other tissue sources may be collected dependent on specific research requirements e.g. CSF, FFPE, saliva, buccal (cheek) cells or hair follicles.
Gene expression is highly dynamic and RNA is highly susceptible to enzymatic degradation. Processing methodologies in the CCB have been chosen to ensure highest quality for each sample type; other considerations include time delays and sample handling procedures during transport from external institutions.
The above details may require refinement or clarification by direct communication with CCB staff. Please contact the CCB directly to discuss further.
An initial database search is carried out by CCB staff after contact by researchers. This search will provide current patient and sample numbers. Researchers can narrow this search to be further project specific, by requesting inclusion or exclusion criteria such as specific WHO classifications; specific time points; biospecimen and sample types; and pertinent pathology test results required.
For further detail on specific holdings or for a more comprehensive breakdown of biospecimen /sample types available for your research project please contact the Tissue Bank Manager directly.
Step 1: Contact CCB staff to discuss samples contained within the CCB and ascertain that the CCB can fulfil the requirements of the proposed research. Please note that a cost recovery/offset charge will apply and a preliminary quote can be provided at this stage.
Step 2: Obtain institutional support and Human Research Ethics Committee approval for your study. If undertaking research in Metro South Health please see this link for more information.
Step 3: Complete an application for biobank samples form (DOC, 1.06 MB). This will include confirmation of the researcher’s institutional HREC approval and the status of funding for their proposed research. The CCB will seek partial cost recovery from sample recipients. Quotes will be provided to researchers at the time of application approval utilising a fee schedule based on processing and storage costs, which may be scaled according to the source of the request (commercial entity vs academic).
Step 4: Lodge the completed application for biobank samples form with the CCB:
Sample requests will be processed as they are received and finalised as soon as possible.
Step 5: Receive evaluation and recommendations from the CCB Management Committee. It is the intention of the CCB Management Committee to supply all reasonable requests when tissue samples are available to maximise the research yield from these samples.
The applicant may wish to lodge a grievance pertaining to applications for samples which are deemed to be duplication of existing work, or are deemed unfeasible or unsuitable by the CCB Scientific Review Committee and/or the CCB Management Committee. Please contact the CCB Manager to discuss further.
Step 6: Samples are made available for dispatch. The samples may undergo extraction and other quality control processes by CCB staff, once a project has been endorsed as suitable. After this process they are dispatched without delay by courier at the expense of the end-user. The following Research Data and Materials Agreement is used prior to coordinating dispatch.
Confirmation of receipt will be requested as well as a quality feedback/assessment report (provided at time of dispatch).
Metro South Health has the potential to link samples with an accurate and complete clinical database, through the iEMR/Digital Hospital, in use at the Princess Alexandra Hospital and other Queensland hospital sites. Information regarding disease features, patient demography, treatments and clinical outcomes are available. De-identified samples could be linked to de-identified information for approved research projects. This is an outstanding resource for researchers translating laboratory findings into clinically meaningful data.
Yes, please see Undertaking Research in Metro South Health for more information.
Institutions and other Queensland hospitals who wish to contribute samples the CCB should contact the CCB Manager on telephone (07) 3176 5835 or by email email@example.com.
All institutions collecting tissue from trial and non-trial patients for the CCB must have first had the CCB Participant Information and Consent Form (PICF) approved by their Human Research Ethics Committee. Please contact the CCB to receive a copy of the PICF.